1 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 |
2 | 250 mg CK-2017357 | - | - | - | - | 2件: 2 2, 11 |
3 | 500 mg CK-2017357 | - | - | - | - | 2件: 2 2, 11 |
4 | Abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
5 | Abatacept Injection | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 2件: 11 11, 46 |
6 | Acetaminophen | 1件: Acetaminophen Acetaminophen | 1件: D00217
D00217
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 13件: 11 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
7 | Acetominofene | - | - | - | - | 2件: 11 11, 63 |
8 | ALN-CC5 | - | - | - | - | 4件: 11 11, 62, 66, 109 |
9 | Aluminium | 1件: Aluminium Aluminium | - | - | - | 2件: 11 11, 46 |
10 | Aluminium hydroxide | 3件: Aluminium Aluminium, Aluminum hydroxide, Hydroxide ion | 1件: D02416
D02416
| - | - | 2件: 11 11, 46 |
11 | Aluminum | 1件: Aluminium Aluminium | - | - | - | 1件: 11 11 |
12 | Aluminum hydroxide | 3件: Aluminium Aluminium, Aluminum hydroxide, Hydroxide ion | 1件: D02416
D02416
| - | - | 1件: 11 11 |
13 | ALXN1210 | - | - | - | - | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
14 | ALXN1830 | - | - | - | - | 3件: 11 11, 35, 61 |
15 | ALXN2050 | - | - | - | - | 2件: 11 11, 62 |
16 | AMIFAMPRIDINA | - | - | - | - | 2件: 3 3, 11 |
17 | Amifampridina fosfato | - | - | - | - | 2件: 3 3, 11 |
18 | Amifampridine | 1件: Amifampridine Amifampridine | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 3件: 3 3, 11, 12 |
19 | Amifampridine Phosphate | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 3件: 3 3, 11, 12 |
20 | Anti-C5 antibody | - | - | - | - | 4件: 11 11, 14, 62, 109 |
21 | Anti-Thymocyte Globulin | - | - | - | - | 18件: 11 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
22 | Apraclonidine | 1件: Apraclonidine Apraclonidine | 1件: D07461
D07461
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
23 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: D07461
D07461
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
24 | ARGX-113 | - | - | - | - | 5件: 11 11, 14, 35, 53, 63 |
25 | ATG (rabbit) | 1件: Rabbit Rabbit | - | - | - | 1件: 11 11 |
26 | AZA | - | - | - | - | 4件: 11 11, 40, 96, 97 |
27 | Azathioprine | 1件: Azathioprine Azathioprine | 1件: D00238
D00238
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
28 | B-peptide-CRM197 conjugate | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
29 | Balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 5件: 6 6, 11, 46, 81, 149 |
30 | Batoclimab | 1件: Batoclimab Batoclimab | 1件: D11983
D11983
| 1件: FCGRT FCGRT 💬 | - | 2件: 11 11, 14 |
31 | Batoclimab 340 mg SC bi-weekly | 1件: Batoclimab Batoclimab | 1件: D11983
D11983
| 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 |
32 | Batoclimab 340 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: D11983
D11983
| 1件: FCGRT FCGRT 💬 | - | 2件: 11 11, 14 |
33 | Batoclimab 680 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: D11983
D11983
| 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 |
34 | BBR 2778 | - | - | - | - | 2件: 11 11, 13 |
35 | BELIMUMAB | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 13件: 11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 |
36 | Benlysta (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 11 11, 49, 53, 222 |
37 | BENLYSTA® (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 11 11, 66, 222 |
38 | Bexsero | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 6件: 11 11, 13, 61, 62, 66, 222 |
39 | BORTEZOMIB | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 17件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331 |
40 | Carmustine | 1件: Carmustine Carmustine | 1件: D00254
D00254
| - | - | 5件: 11 11, 13, 14, 28, 60 |
41 | CD19-directed humanised afucosylated monoclonal antibody | - | - | - | - | 1件: 11 11 |
42 | CELLCEPT | - | - | - | - | 5件: 11 11, 13, 42, 43, 49 |
43 | CellCept 500 mg | - | - | - | - | 1件: 11 11 |
44 | CellCept 500 mg film-coated tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: D00752
D00752
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 |
45 | CellCept 500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: D00752
D00752
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 |
46 | CellCept®500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: D00752
D00752
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 |
47 | Cemdisiran | 1件: Cemdisiran Cemdisiran | - | - | - | 4件: 11 11, 62, 66, 109 |
48 | CFZ533 | - | - | - | - | 4件: 11 11, 46, 49, 53 |
49 | Chloride | 1件: Chloride ion Chloride ion | - | - | - | 28件: 6 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 288, 296, 297, 299, 338 |
50 | CLADRIBINE | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 11 11, 13, 94 |
51 | Cladrybine | - | - | - | - | 1件: 11 11 |
52 | Corynebacterium diphtheriae | 1件: Corynebacterium diphtheriae Corynebacterium diphtheriae | - | - | - | 1件: 11 11 |
53 | CRM197 | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 3件: 11 11, 13, 46 |
54 | CT103A cells | - | - | - | - | 2件: 11 11, 13 |
55 | CV-MG01 | 1件: CV-MG01 CV-MG01 | - | - | - | 1件: 11 11 |
56 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 |
57 | Cyclophosphamide and fludarabine | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 3件: D00287
D00287
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 11 11, 13 |
58 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
59 | Cytarabine | 1件: Cytarabine Cytarabine | 1件: D00168
D00168
| - | - | 7件: 11 11, 13, 14, 25, 49, 60, 65 |
60 | DAS-001 | - | - | - | - | 1件: 11 11 |
61 | Descartes-08 | - | - | - | - | 1件: 11 11 |
62 | Difenidramina | - | - | - | - | 2件: 11 11, 63 |
63 | DIFENIDRAMINA CLORIDRATO | - | - | - | - | 3件: 11 11, 19, 63 |
64 | Diphenhydramine | 1件: Diphenhydramine Diphenhydramine | 1件: D00300
D00300
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 8件: 11 11, 13, 49, 51, 70, 86, 222, 256 |
65 | Diphenhydramine hydrochloride | 1件: Diphenhydramine Diphenhydramine | 1件: D00300
D00300
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 11 11, 49 |
66 | ECULIZUMAB | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 11 11, 13, 14, 61, 62, 109, 222 |
67 | EFALIZUMAB | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 8件: 11 11, 13, 37, 46, 53, 61, 95, 96 |
68 | Efedrina | 1件: Ephedrine Ephedrine | 1件: D00124
D00124
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
69 | Efgartigimod | - | - | - | - | 4件: 11 11, 35, 53, 63 |
70 | EFGARTIGIMOD ALFA | 1件: Efgartigimod alfa Efgartigimod alfa | 1件: D11876
D11876
| 1件: FCGRT FCGRT 💬 | - | 6件: 11 11, 14, 35, 53, 63, 162 |
71 | Efgartigimod concentrate for solution for infusion 20 mg/mL | - | - | - | - | 1件: 11 11 |
72 | Efgartigimod IV | - | - | - | - | 1件: 11 11 |
73 | Efgartigimod PH20 SC | - | - | - | - | 5件: 11 11, 14, 35, 63, 162 |
74 | EN101 | - | - | - | - | 1件: 11 11 |
75 | Ephedrine | 1件: Ephedrine Ephedrine | 1件: D00124
D00124
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
76 | EPHEDRINE HYDROCHLORIDE | 1件: Ephedrine Ephedrine | 1件: D00124
D00124
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
77 | Etoposide | 1件: Etoposide Etoposide | 1件: D00125
D00125
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 11件: 11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
78 | Famciclovir | 1件: Famciclovir Famciclovir | 1件: D00317
D00317
| - | - | 2件: 11 11, 13 |
79 | Fc- and CDR-modified humanised monoclonal antibody against C5 | - | - | - | - | 3件: 11 11, 62, 109 |
80 | Firdapse | 1件: Amifampridine Amifampridine | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 |
81 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 |
82 | Fludarabine | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 19件: 11 11, 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
83 | Fusion | 1件: Iron polymaltose Iron polymaltose | - | - | - | 7件: 11 11, 13, 46, 49, 69, 70, 271 |
84 | G-CSF | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 16件: 2 2, 6, 11, 13, 16, 22, 47, 51, 60, 62, 65, 85, 96, 284, 285, 331 |
85 | GAMUNEX 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
86 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 |
87 | Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms | - | - | - | - | 1件: 11 11 |
88 | Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) | - | - | - | - | 1件: 11 11 |
89 | GSK1550188 | - | - | - | - | 4件: 11 11, 49, 66, 222 |
90 | HBM9161 Injection (340 mg) | - | - | - | - | 1件: 11 11 |
91 | HBM9161 Injection (680mg and 340 mg) | - | - | - | - | 1件: 11 11 |
92 | HBM9161 Injection (680mg) | - | - | - | - | 1件: 11 11 |
93 | Hematopoietic Stem Cell Transplantation | - | - | - | - | 12件: 11 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
94 | Hidrocloruro de efedrina | 1件: Ephedrine Ephedrine | 1件: D00124
D00124
| 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
95 | HIZENTRA ® | - | - | - | - | 1件: 11 11 |
96 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
97 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 |
98 | Human normal immunoglobulin G (IgG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
99 | Hydroxide | 1件: Hydroxide ion Hydroxide ion | - | - | - | 5件: 11 11, 46, 96, 97, 284 |
100 | IGIV-C | - | - | - | - | 1件: 11 11 |
101 | Immune globulin | - | - | - | - | 3件: 11 11, 13, 14 |
102 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
103 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
104 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 |
105 | INEBILIZUMAB | 1件: Inebilizumab Inebilizumab | 1件: D11757
D11757
| 1件: CD19 CD19 💬 | 5件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | 4件: 11 11, 13, 51, 300 |
106 | Influenza vaccine | - | - | - | - | 5件: 11 11, 13, 46, 51, 84 |
107 | Intravenous ImmuneGlobulin | - | - | - | - | 1件: 11 11 |
108 | Intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) | - | - | - | - | 1件: 11 11 |
109 | IVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 7件: 11 11, 13, 14, 17, 50, 51, 65 |
110 | JNJ-80202135 | - | - | - | - | 4件: 11 11, 46, 49, 53 |
111 | Leflunomide | 1件: Leflunomide Leflunomide | 1件: D00749
D00749
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 12件: 11 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 |
112 | M281 | - | - | - | - | 5件: 11 11, 46, 49, 53, 61 |
113 | M281 Injection | - | - | - | - | 1件: 11 11 |
114 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
115 | Magnesium | 1件: Magnesium Magnesium | - | - | - | 15件: 6 6, 11, 46, 64, 70, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
116 | Magnesium sulfate | 3件: Magnesium gluconate Magnesium gluconate, Magnesium sulfate, Sulfate ion | 2件: D01108
D01108
,
D04835
| - | - | 3件: 11 11, 296, 297 |
117 | Melphalan | 1件: Melphalan Melphalan | 1件: D00369
D00369
| - | - | 15件: 11 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 |
118 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
119 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
120 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
121 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
122 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
123 | Menveo | 1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | - | - | - | 6件: 11 11, 13, 61, 62, 66, 222 |
124 | Mesna | 1件: Coenzyme M Coenzyme M | - | - | - | 10件: 11 11, 13, 44, 45, 51, 60, 65, 85, 96, 164 |
125 | Mestinon | 1件: Pyridostigmine Pyridostigmine | - | - | - | 3件: 3 3, 6, 11 |
126 | Methotrexate | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
127 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
128 | Metilprdnisolone | - | - | - | - | 1件: 11 11 |
129 | METILPREDNISOLONE | - | - | - | - | 6件: 11 11, 13, 53, 56, 63, 300 |
130 | MG-O-1002 | - | - | - | - | 1件: 11 11 |
131 | MONARSEN | 1件: Monarsen Monarsen | - | - | - | 1件: 11 11 |
132 | MONITOR | 1件: Methamidophos Methamidophos | - | - | - | 4件: 2 2, 11, 81, 129 |
133 | MuSK-CAART | - | - | - | - | 1件: 11 11 |
134 | Mutagrip | - | - | - | - | 2件: 11 11, 13 |
135 | Mycophenolate | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
136 | Mycophenolate mofetil | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: D00752
D00752
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
137 | Mycophenolate mofetil (CellCept) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: D00752
D00752
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 11 11, 13 |
138 | Mycophenolate mofetil [CellCept] | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: D00752
D00752
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 |
139 | Mycophenolic acid | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 8件: 11 11, 43, 49, 51, 60, 66, 96, 222 |
140 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO | - | - | - | - | 1件: 11 11 |
141 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide, Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein, Hydroxide ion | 1件: D02416
D02416
| - | - | 1件: 11 11 |
142 | Nipocalimab | 1件: Nipocalimab Nipocalimab | 1件: D11666
D11666
| 1件: FCGRT FCGRT 💬 | - | 6件: 11 11, 14, 46, 49, 53, 61 |
143 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 |
144 | Oxaloacetate | 1件: Oxaloacetic acid Oxaloacetic acid | - | - | - | 2件: 6 6, 11 |
145 | PARACETAMOLO | - | - | - | - | 9件: 2 2, 11, 14, 19, 28, 53, 61, 63, 300 |
146 | Phosphate | 1件: Phosphate ion Phosphate ion | - | - | - | 32件: 2 2, 3, 6, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299 |
147 | PIXANTRONE | 1件: Pixantrone Pixantrone | 1件: D05522
D05522
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 2件: 11 11, 13 |
148 | Placebo | - | - | - | - | 28件: 3 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
149 | Pozelimab | 1件: Pozelimab Pozelimab | 1件: D11477
D11477
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 2件: 11 11, 62 |
150 | Pozelimab + Cemdisiran | 2件: Cemdisiran Cemdisiran, Pozelimab | 1件: D11477
D11477
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 11 11 |
151 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
152 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
153 | Prednisone - Azathioprine | 2件: Azathioprine Azathioprine, Prednisone | 2件: D00238
D00238
,
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 11 11 |
154 | Prednisone alone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 11 11, 66 |
155 | PRIVIGEN | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 51, 65 |
156 | PRN2246 | - | - | - | - | 2件: 11 11, 13 |
157 | Pyridostigmine | 1件: Pyridostigmine Pyridostigmine | - | - | - | 4件: 3 3, 6, 11, 256 |
158 | Pyridostigmine, Prednisone, Tacrolimus | 3件: Prednisone Prednisone, Pyridostigmine, Tacrolimus | 3件: D00107
D00107
,
D00473
,
D08556
| 6件: NR3C1 NR3C1, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 34件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
159 | Pyridostigmine, Tacrolimus | 2件: Pyridostigmine Pyridostigmine, Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
160 | Rabbit | 1件: Rabbit Rabbit | - | - | - | 8件: 11 11, 13, 49, 51, 60, 65, 96, 285 |
161 | Raptiva | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 9件: 11 11, 13, 37, 46, 49, 53, 61, 95, 96 |
162 | Raptiva 100 mg/ml powder and solvent for solution for injection | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 7件: 11 11, 13, 46, 53, 61, 95, 96 |
163 | RAVULIZUMAB | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
164 | RC18 160mg | - | - | - | - | 3件: 11 11, 13, 66 |
165 | RC18 240 mg | - | - | - | - | 2件: 11 11, 53 |
166 | RECOMBINANT NEISSERIA | - | - | - | - | 1件: 11 11 |
167 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E.COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE | 4件: Aluminium Aluminium, Aluminum hydroxide, Hydroxide ion, Iron polymaltose | 1件: D02416
D02416
| - | - | 1件: 11 11 |
168 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN | - | - | - | - | 1件: 11 11 |
169 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN | 1件: Iron polymaltose Iron polymaltose | - | - | - | 2件: 11 11, 13 |
170 | REGN3918 | - | - | - | - | 2件: 11 11, 62 |
171 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
172 | Rituximab (Rituxan) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 11 11 |
173 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 |
174 | RO5333787 | - | - | - | - | 2件: 11 11, 13 |
175 | ROZANOLIXIZUMAB | 1件: Rozanolixizumab Rozanolixizumab | 1件: D12182
D12182
| 1件: FCGRT FCGRT 💬 | - | 3件: 11 11, 14, 63 |
176 | RTX | - | - | - | - | 5件: 11 11, 46, 65, 222, 240 |
177 | RVT-1401 | - | - | - | - | 2件: 11 11, 61 |
178 | Salbutamol | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 3 3, 11, 49, 85, 86, 111, 256, 299 |
179 | Salbutamol 4Mg Tablet | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
180 | SALBUTAMOL SULFATE PH. EUR. | 2件: Salbutamol Salbutamol, Sulfate ion | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
181 | Salbutamol WZF 4 mg | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
182 | SAR442168 | - | - | - | - | 2件: 11 11, 13 |
183 | SATRALIZUMAB | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 11 11, 13, 86 |
184 | Sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 20件: 6 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 168, 193, 227, 228, 288, 299 |
185 | Sodium Chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 4件: 11 11, 13, 51, 228 |
186 | SOLIRIS | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 11 11, 13, 14, 61, 62, 109, 222 |
187 | Subcutaneous immunoglobulin (SCIG) | - | - | - | - | 1件: 11 11 |
188 | Subcutaneous immunoglobulins | - | - | - | - | 1件: 11 11 |
189 | Sulfate | 1件: Sulfate ion Sulfate ion | - | - | - | 27件: 2 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 85, 86, 96, 111, 218, 222, 224, 226, 265, 296, 297, 299 |
190 | Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
191 | T-peptide-CRM197 conjugate | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
192 | Tacrolimus | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
193 | Tacrolimus capsule | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 |
194 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 |
195 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 |
196 | Tetanus vaccin | - | - | - | - | 1件: 11 11 |
197 | Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
198 | Tocilizumab Injectable Product | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 11 11 |
199 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
200 | Tofacitinib 5 MG | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 4件: 11 11, 40, 46, 271 |
201 | Tolebrutinib | - | - | - | - | 2件: 11 11, 13 |
202 | Tolebrutininb | - | - | - | - | 1件: 11 11 |
203 | UCB7665 | - | - | - | - | 3件: 11 11, 14, 63 |
204 | Ultomiris | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 6件: 2 2, 11, 13, 50, 62, 66 |
205 | Ultomiris 1,100 mg/11 mL | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 11 11 |
206 | Uplizna | 1件: Inebilizumab Inebilizumab | 1件: D11757
D11757
| 1件: CD19 CD19 💬 | 5件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | 2件: 11 11, 300 |
207 | Velamox | - | - | - | - | 1件: 11 11 |
208 | Velcade | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 3件: 11 11, 28, 61 |
209 | Velcade® | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 11 11 |
210 | Zilucoplan | 1件: Zilucoplan Zilucoplan | 1件: D12357
D12357
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 2 2, 11, 62 |
211 | Zilucoplan (RA101495) | 1件: Zilucoplan Zilucoplan | 1件: D12357
D12357
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 2件: 11 11, 62 |